Niktimvo (axatilimab-csfr) is a first-in-class colony stimulating factor-1 receptor (CSF-1R)-blocking antibody approved for use in the U.S. for the treatment of chronic graft-versus-host disease (GVHD ...

Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ETCompany ParticipantsRob Eno - CEOTim Cruickshank - CFOLarry Holub ...